B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcγRIIb, which are modulated by anti-tumor necrosis factor therapy by Catalán, Diego et al.
RESEARCH ARTICLE Open Access
B cells from rheumatoid arthritis patients show
important alterations in the expression of CD86
and FcgRIIb, which are modulated by anti-tumor
necrosis factor therapy
Diego Catalán
1, Octavio Aravena
1, Francisca Sabugo
2, Pamela Wurmann
2, Lilian Soto
2, Alexis M Kalergis
3,
Miguel Cuchacovich
2, Juan C Aguillón
1*, Millenium Nucleus on Immunology and Immunotherapy P-07-088-F
Abstract
Introduction: Several molecules help preserve peripheral B cell tolerance, but when altered, they may predispose
to autoimmunity. This work studied the expression of the costimulatory molecule CD86 and the inhibitory receptor
for IgG immune complexes FcgRIIb (CD32b), on B cells from rheumatoid arthritis (RA) patients, and the influence of
anti-tumor necrosis factor (TNF) therapy.
Methods: Peripheral B cells from 18 RA patients and 13 healthy donors were characterized using flow cytometry.
Eleven patients who underwent a six-month adalimumab therapy were further assessed for phenotypic changes
on their B cells.
Results: RA patients exhibited a high percentage of naïve and memory B cells expressing CD86. In contrast,
expression of FcgRIIb was significantly reduced on RA memory B cells and plasmablasts as compared to healthy
donors, probably due to downregulation of this receptor when differentiating from naïve to memory cells. These
alterations on FcgRIIb were associated with high levels of anti-citrullinated vimentin autoantibodies. In addition,
treatment with adalimumab normalized the expression of CD86 on memory B cells and reduced the expression of
FcgRIIb, mainly on naïve B cells.
Conclusions: Our findings show that peripheral B cells from RA patients have an altered expression of key
molecules, such as CD86 and FcgRIIb. Because this latter receptor is required for feedback inhibition, a deficient
expression might contribute to humoral autoimmune responses. Furthermore, these molecules are likely to be
influenced by inflammatory factors, since they were modulated by TNF inhibition.
Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory,
and autoimmune disease that affects mainly synovial
joints, leading to progressive destruction, pain, and dis-
ability. It is well known from mouse models that B cells
play a pivotal role in the development of the autoim-
mune process as a precursor of antibody-secreting cells
but also as antigen-presenting cells (APCs) [1,2].
Immune cells express an array of receptors that bind the
Fc portion of IgG-containing immune complexes (FcgRs).
Particularly, it has been stated that B cells and plasma cells
express only the low-affinity receptor FcgR I I b ,w h i c h ,i n
contrast to FcgRIIa, has an immunoreceptor tyrosine-
based inhibitory motif on the cytoplasmic domain. This
characteristic confers an inhibitory function to the recep-
tor which is essential in several checkpoint stages in which
abnormal humoral responses are quenched by mechan-
isms that include the deletion of autoreactive clones and
feedback inhibition of IgG secretion [3].
Given this property, it is not surprising that these
molecules have been involved in autoimmune processes.
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morphisms in the regulatory regions of the FcgRIIb
gene, which result in a reduced expression of the recep-
tor on germinal center B cells [4]. Moreover, depending
on the strain, mice deficient in FcgRIIb can sponta-
neously develop a lupus-like syndrome, become suscep-
tible to collagen-induced arthritis (CIA), or develop a
severe phenotype of CIA or experimental autoimmune
encephalomyelitis [5-8]. In contrast, overexpression of
FcgRIIb on B cells, but not on macrophages, leads to
an early resolution of CIA and reduced spontaneous
lupus [9].
On the other hand, human autoimmune diseases char-
acterized by a deregulated secretion of autoantibodies,
such as systemic lupus erythematosus (SLE) and RA,
have been associated with abnormalities in FcgRIIb reg-
ulation. Polymorphisms in the promoter region as well
as in the transmembrane domain of the FcgRIIb gene
have been described to affect the expression and func-
tion of this receptor, respectively [10-12]. While both
polymorphisms in FcgRIIb are associated with SLE
occurrence [10,13], the one on the transmembrane
domain is also associated with joint damage in RA [14].
Although alterations in the expression of FcgRIIb on B
cells have been described for other autoimmune diseases
[15-18], no data about RA are available.
The aim of our study was to evaluate the phenotype of
B cells from RA patients, focusing on their activation
status and their expression of FcgRIIb. These parameters
were compared with those obtained from B cells of
healthy individuals. In addition, we followed up on these
patients during anti-tumor necrosis factor (anti-TNF)
therapy and assessed the phenotype of their B cells after
6 months of treatment. Our findings show that B cells
from RA patients are activated, as reflected by the
expression of CD86. We have also observed an altered
expression of FcgRIIb, which is associated with the pre-
sence of autoantibodies. These abnormalities were
shown to be partially reverted by anti-TNF therapy.
Materials and methods
Patients
We recruited 18 patients meeting the American College
of Rheumatology criteria for RA [19]. All of the patients
were women, with a mean ± standard deviation (SD)
age of 52.8 ± 10.5 years and disease duration of 16.3 ± 7
years at study entry. All of them exhibited an active dis-
ease defined as at least six swollen joints, at least nine
tender joints, and morning stiffness for more than 1
hour, regardless of being under treatment with disease-
modifying antirheumatic drugs. Disease activity was
determined based on the disease activity score for 28
joints (DAS-28) [20]. Thirteen patients received 40 mg
of adalimumab (kindly provided by Abbott Laboratories,
Abbott Park, IL, USA) subcutaneously every other week
during 24 weeks. The European League Against Rheu-
matism (EULAR) response criteria were used to estab-
lish the degree of response to treatment [21]. Thirteen
healthy women were recruited as a control group, with
a mean ± SD age of 39.4 ± 9.7 years. For the analyses of
CD86 expression, we had available samples of only 8 of
the 13 healthy donors. Blood samples for flow cytometry
analyses and serum determinations were drawn from RA
patients at study entry and 6 months after beginning
adalimumab administration. The study was approved by
the Ethical Committee of the Hospital Clínico Universi-
dad de Chile, and all patients and controls gave their
written informed consent.
Serum antibody determination
Serum antibodies against modified and citrullinated
vimentin (anti-MCV) were measured using a commer-
cial enzyme-linked immunosorbent assay (ELISA) kit
(Orgentec, Mainz, Germany) in accordance with the
instructions of the manufacturer. The cutoff level was
set at 20 U/mL. Serum anti-cyclic citrullinated peptide
(ccp) antibodies were detected using a commercial sec-
ond-generation ELISA (Axis-Shield, Dundee, Scotland)
in accordance with the instructions of the manufacturer.
A cutoff level of 5 U/mL was considered. Total serum
IgG levels were measured by ELISA at the Immunology
Laboratory of the Hospital Clínico Universidad de Chile,
and the range of concentrations considered normal was
639 to 1,349 mg/dL.
B-lymphocyte phenotyping
We characterized B cells using the following monoclo-
nal anti-human antibodies: anti-CD19 phycoerythrin
(PE) cyanine 5 (Cy5), anti-CD27 fluorescein isothiocya-
nate (FITC), anti-CD27 PE, anti-CD86 FITC (BD Bios-
ciences, San Jose, CA, USA), and anti-FcgRII PE (clone
7.3; Fitzgerald Industries International, Acton, MA,
USA). For the staining procedure, anticoagulated whole
blood was incubated with fluorescent antibodies for 30
minutes at 4°C. Subsequently, red cells were lysed with
ammonium chloride potassium (ACK) buffer, washed,
and fixed for flow cytometry (FACSCalibur; BD Bios-
ciences, San Jose, CA, USA). Data were analyzed with
WinMDI 2.9 Software (TSRI Flow Cytometry Core
Facility, La Jolla, CA, USA). A region was set to define
the lymphocytic population according to forward and
side scatter patterns. B cells were defined as CD19-
expressing cells, and a second region was set for them,
while CD27 was used to discriminate memory from
naïve subsets. Plasmablasts were defined as CD19
low
CD27
high-expressing cells (Figure 1a). Mean fluores-
cence intensity (MFI) was used as the analysis para-
meter for the expression of FcgRIIb.
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All of the study variables were tested for normality with
the Shapiro-Wilk test. Differences between patient and
control groups were analyzed using the two-tailed
unpaired Student t test or Mann-Whitney U test, when
appropriate. For comparisons between different B-cell
subsets and for different adalimumab therapy time
points, the two-tailed paired Student t test or Wilcoxon
signed-rank test were used, when appropriate. Correla-
tions were evaluated with a two-tailed Spearman corre-
lation test. For contingency analyses, a two-sided Fisher
exact test was used. P values of less than 0.05 were con-
sidered significant. For statistic analyses and graphics,
GraphPad Prism 4 software (GraphPad Software, Inc.,
La Jolla, CA, USA) was used.
Results
Rheumatoid arthritis patients show peripheral B-cell
frequencies similar to those of healthy controls
Abnormalities in the frequency of B cells and in the
proportion of different B-cell subsets in autoimmune
diseases have been previously reported [22,23]. Despite a
broad dispersion, we found no significant differences
between RA and control subjects when comparing the
percentage of B cells in the lymphocytic population
(mean percentage ± SD 7.5 ± 3.1 and 9 ± 2.2, respec-
tively). Furthermore, when we discriminated B cells in
naïve cells, memory cells and plasmablasts by means of
CD19 and CD27 staining, we detected similar percen-
tages of these subsets in the two groups of individuals
(Figure 1).
Higher frequency of activated naïve and memory B cells
in rheumatoid arthritis patients than in healthy controls
To assess the activation level of circulating B lympho-
cytes from RA patients, we analyzed CD86, a co-stimu-
latory molecule that increases its expression on B-cell
surface upon activation [24,25]. We observed that RA
patients have more CD86-expressing cells on the naïve
and memory subsets than healthy controls do (P =
0.042 and P = 0.017, respectively), while no significant
differences were observed for plasmablasts (Figure 2).
Figure 1 Characterization of B-cell subpopulations from rheumatoid arthritis (RA) patients and healthy controls (HCs). (a) Dot plot
representing the distribution of naïve B cells (R3), memory B cells (R4), and plasmablasts (R5) which was used on further analyses. No differences
in the percentages of naïve B cells (b), memory B cells (c), and plasmablasts (d) between 18 RA patients and 13 HCs were detected. P > 0.05,
two-tailed unpaired Student t test. Horizontal lines represent mean values.
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representative of the expression of CD86 on B cells from an RA patient (left) and a healthy control (HC) (right). The number in the quadrant
represents the percentage of CD19
+ CD86
+ cells. Graphics summarizing the percentages of CD86
+ cells among naïve B cells (b), memory B cells
(c), and plasmablasts (d) from 18 RA patients and 9 HCs. *P < 0.05, two-tailed Mann-Whitney U test. Horizontal lines represent mean values.
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plasmablasts from rheumatoid arthritis patients
As for CD86, the evaluation of FcgRIIb expression was
carried out by analyzing each B-cell subset individually.
We found that, although naïve B cells from RA patients
and controls expressed similar levels of this receptor, its
expression was significantly lower on RA memory B
cells and plasmablasts (P = 0.0005 and P = 0.0013,
respectively) (Figure 3). No correlations were observed
between FcgRIIb expression on B cells and disease activ-
ity or percentage of CD86-expressing B cells (data not
shown).
There is evidence of a normal upregulation of FcgRIIb
following naïve B-cell activation and differentiation to a
memory cell [15]. In our sample of healthy subjects, we
detected that most individuals upregulate the expression
of FcgRIIb from naïve to memory B cells (8/13), in con-
trast with the RA group, in which 15 out of 18 patients
were downregulators (ΔMFI of greater than 10 between
naïve and memory populations) (P = 0.029). This
decrease of FcgRIIb expression on memory B cells as
compared with naïve B cells from RA patients was sta-
tistically significant (P = 0.0001) (Figure 4b). We also
noticed that RA patients show a further decrease in
FcgRIIb expression on plasmablasts in comparison with
memory B cells (P = 0.0001) (Figure 4b). A similar
reduction was observed in healthy controls (P = 0.0002)
(Figure 4c), although the expression levels reached by
the healthy controls were still higher than those exhib-
ited by RA patients (Figure 3c).
FcgRIIb expression on B cells is associated with
autoantibody levels
As one of the main functions of FcgRIIb on B cells is to
control the development of autoimmunity by providing
feedback inhibition in order to limit the secretion of
autoantibodies, we assessed whether the levels of auto-
antibodies on RA patients were related to the expression
of this inhibitory receptor on B cells. For this purpose,
we measured serum anti-MCV antibodies since they
have been described to be highly specific for RA [26].
Interestingly, RA patients negative for serum anti-MCV
antibodies or with low levels (less than 50 U/mL) dis-
played a higher expression of FcgRIIb but only on mem-
ory B cells (P = 0.048) (Figure 5a). Also, we found that
all three patients who did not downregulate FcgRIIb
from naïve to memory B cells exhibited no or very low
titers of anti-MCV antibodies (P = 0.033) (Figure 5b).
We obtained similar results when we measured anti-ccp
antibodies (data not shown). To evaluate whether this
association was restricted to autoantibodies, we com-
pared FcgRIIb expression on memory B cells in patients
with normal (less than 1,350 mg/dL) or high (at least
1,350 mg/dL) levels of total serum IgG without
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Figure 3 Decreased expression of FcgRIIb on memory B cells
and plasmablasts from rheumatoid arthritis (RA) patients.
Graphics summarize the expression of FcgRIIb on naïve B cells (a),
memory B cells (b), and plasmablasts (c) from 18 RA patients and
13 healthy controls (HCs). Expression was quantified as mean
fluorescence intensity (MFI). **P < 0.01, ***P < 0.001, two-tailed
unpaired Student t test. Horizontal lines represent mean values.
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(Figure 5c).
Anti-tumor necrosis factor therapy can influence B-cell
phenotype in rheumatoid arthritis patients
Next, we wanted to evaluate whether the alterations
observed on RA patients’ B cells could be reverted by
the treatment with adalimumab. Of the 13 RA patients
who completed 6 months of treatment with an anti-
TNF antibody (adalimumab), only 11 exhibited at least a
moderate response according to the EULAR response
criteria. In these patients, the percentage of total B cells
as well as the proportion of naïve, memory, or plasma-
blast subsets remained unchanged (data not shown).
However, the anti-TNF therapy caused a decrease in the
proportion of memory B cells expressing CD86 after 6
months of therapy (P = 0.032) (Figure 6a). Notably, the
change affecting CD86 paralleled a reduction in the
intensity of FcgRIIb expression, but this decrease
reached significance on the naïve B-cell subpopulation
only (P = 0.003) (Figure 6b). Consequently, there was an
attenuation of the receptor downregulation observed
Figure 4 Altered regulation of FcgRIIb on B cells from rheumatoid arthritis (RA) patients. (a) Representative histograms of FcgRIIb (CD32b)
expression on naïve B cells (gray line), memory B cells (black line), and plasmablasts (dotted line) from an RA patient (left) and a healthy control
(right). The shaded curve represents the isotype control. Graphics show a comparison of FcgRIIb expression between naïve B cells, memory B
cells, and plasmablasts from 18 RA patients (b) and 13 healthy controls (c). Expression was quantified as mean fluorescence intensity (MFI). The
differences in the FcgRIIb expression levels between B-cell subpopulations were analyzed with the two-tailed paired Student t test; ***P < 0.001.
Horizontal lines represent mean values. PE, phycoerythrin.
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but the difference between naïve and memory B cells
was still significant (P = 0.046) (Figure 6c). In addition,
anti-MCV antibody titers remained stable throughout
this period (Figure 6d).
Discussion
In the present work, we provide evidence that phenoty-
pic alterations on B cells from RA patients affect key
molecules involved in the regulation of antigen presen-
tation and antibody secretion functions. A major role of
B cells in the development and perpetuation of RA has
been consistently demonstrated with the appearance of
B cell-depleting therapy and its impressive results in
reducing symptoms and preventing disease progression
[27]. Studies on murine models have suggested that
antigen-specific B cells are required as APCs for the
induction of autoimmune arthritis, owing to their
expression of MHC (major histocompatibility complex)
class II and co-stimulatory molecules CD80 and CD86
[28,29]. CD86 is upregulated on activated B cells upon
B-cell receptor (BCR) and CD19/CD21 complex engage-
ment [24,25]. Our results show that RA patients have a
higher proportion of naïve and memory B cells expres-
sing CD86 than healthy controls, reflecting an expanded
activated status within these subpopulations, which is
likely to favor a more productive interaction with patho-
genic T cells. Analogous results have been reported for
other inflammatory diseases, such as SLE [30-33], sys-
temic sclerosis [34], asthma [35], and irritable bowel
syndrome [36]. Presumably, constant stimulation of
autoantigens through BCR and the influence of other
proinflammatory signals, such as stimulation through
Toll-like receptors (TLRs) [37], give rise to this activated
phenotype. Also, it is probable that the effect of these
activation stimuli could be attenuated by the cross-link-
ing of IgG-containing immune complexes to their inhi-
bitor receptor, FcgRIIb, since studies on dendritic cells
( D C s )h a v ed e m o n s t r a t e dt h a te x p o s u r et oi m m u n e
complexes together with a blockage of FcgRIIb is suffi-
cient to induce an increase in the expression of CD86
[38,39], whereas the overexpression of this receptor on
murine B cells reverses the induction of CD86 triggered
via BCR [9]. However, in a multifactorial complex dis-
ease such as RA, it is expected that the expression of
this or other activation markers is influenced by a vari-
ety of factors as it is suggested by the absence of corre-
lation between CD86-expressing B cells and FcgRIIb
expression levels found in our patients.
Our data show that RA patients present reduced levels
of FcgRIIb on memory B cells and plasmablasts com-
pared with healthy donors. This phenomenon can be
explained by the abnormal downregulation of this recep-
tor from naïve to memory B cells which we observed in
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Figure 5 FcgRIIb expression levels on rheumatoid arthritis (RA)
patients’ memory B cells are inversely associated with anti-
modified and citrullinated vimentin (anti-MCV) titers. (a) FcgRIIb
expression on memory B cells from RA patients with high titers (at
least 50 U/mL) and from those with no or low titers (less than 50
U/mL) of serum anti-MCV antibodies. Expression was quantified as
mean fluorescence intensity (MFI). *P < 0.05, two-tailed Mann-
Whitney U test. (b) Anti-MCV antibody titers in patients who
downregulated the expression of FcgRIIb (the difference between
MFI of naïve B cells and MFI of memory B cells was greater than 10
for downregulators) and in those who upregulated or maintained it
almost invariable (the difference between MFI of naïve B cells and
MFI of memory B cells was not greater than 10 for non-
downregulators). *P < 0.05, two-tailed Mann-Whitney U test. (c)
FcgRIIb expression on memory B cells from RA patients with normal
levels (less than 1,350 mg/dL) and high levels (at least 1,350 mg/dL)
of total serum IgG. Expression was quantified as MFI. P > 0.05, two-
tailed Mann-Whitney U test. Horizontal lines represent mean values.
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Figure 6 B-cell phenotype and anti-modified and citrullinated vimentin (anti-MCV) titers on rheumatoid arthritis (RA) patients after 6
months of adalimumab therapy. After 6 months of anti-tumor necrosis factor (anti-TNF) therapy, B-cell phenotype and serum anti-MCV
antibodies from 11 RA patients, who exhibited at least a moderate response to the treatment, were reassessed. (a) Graphics summarizing the
percentages of CD86
+ cells among naïve B cells, memory B cells, and plasmablasts from RA patients before and after 6 months of anti-TNF
therapy. *P < 0.05, two-tailed Wilcoxon signed-rank test. (b) Graphics summarizing FcgRIIb expression on naïve B cells, memory B cells, and
plasmablasts from RA patients before and after 6 months of anti-TNF therapy. Expression was quantified as mean fluorescence intensity (MFI). **P
< 0.01, two-tailed paired Student t test. (c) Comparison of FcgRIIb expression between naïve B cells, memory B cells, and plasmablasts from RA
patients after anti-TNF therapy. The differences in FcgRIIb expression levels between B-cell subpopulations were analyzed with the two-tailed
paired Student t test; *P < 0.05, **P < 0.01, ***P < 0.001. (d) Comparison of serum anti-MCV antibody levels before and after 6 months of anti-
TNF therapy. P > 0.05, two-tailed paired Student t test. Horizontal lines represent mean values.
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seen in SLE and chronic inflammatory demyelinating
polyneuropathy, other autoimmune diseases character-
ized by uncontrolled secretion of autoantibodies [15-18].
It has been postulated that FcgRIIb upregulation might
constitute a critical checkpoint in peripheral tolerance
by providing an inhibitory feedback that limits the
ongoing humoral response to self-antigens. In fact, in
lupus-prone mice, the restoration of FcgRIIb levels on B
cells can revert the secretion of autoantibodies and renal
disease [40]. Furthermore, the expression of this inhibi-
tory receptor specifically on B cells, but not on macro-
phages, can be determinant for controlling
autoimmunity in models of arthritis and lupus [9].
Through this work, we provide new evidence that may
help to reinforce this concept as we have revealed, for
the first time, an association between high levels of
FcgRIIb on memory B cells and no or low titers of spe-
cific autoantibodies, anti-MCV antibodies. This interest-
ing result appears to be exclusive for autoimmune
responses since we did not find a similar association
when analyzing total IgG levels. It is noteworthy to con-
sider that in this study we have examined only the
expression of FcgRIIb, but not its function, which if
altered could also affect the regulatory ability over the
humoral response against citrullinated proteins. Like-
wise, a recent publication has demonstrated an associa-
tion between a functional polymorphism for FcgRIIb and
anti-ccp (+) RA in an Asian population [41].
After patients underwent 6 months of therapy with an
anti-TNF antibody, we observed a decrease in CD86-
expressing memory B cells, reflecting an attenuation of
the B-cell activated status. Paradoxically, FcgRIIb expres-
sion on the naïve B-cell subset also decreased signifi-
cantly. It has been demonstrated that FcgRIIa and
FcgRIIb on human monocytes are differentially regulated
by Th1/Th2 cytokines, with interferon-gamma favoring
the activator receptor and interleukin-4 favoring the
inhibitory receptor [42]. On the other hand, TNF down-
modulates FcgRIIb and FcgRIIa on monocytes, not
affecting FcgRIIa but reducing FcgRIIb expression on
DCs, while increasing FcgRIIa without changing FcgRIIb
on neutrophils, indicating a tight cell-specific regulation
[43-47]. To our knowledge, no studies addressing the
effect of TNF over FcgRIIb on human B cells have been
published, but our results strongly suggest that TNF or
other downstream cytokines may influence the expres-
sion of this receptor on B lymphocytes. In regard to RA,
exposure of DCs to synovial fluid from RA patients has
been shown to lead to an upregulation of FcgRIIb [14]
and an elevated expression of FcgRIIb has been demon-
strated on RA synovial tissue, probably counteracting
the upregulation of other activating receptors [48].
Some studies have reported that FcgR expression levels
on leukocytes can vary with anti-rheumatic drugs, which
w o u l dp r o m o t eam o r ei n h i b i t o r yp r o f i l e[ 4 8 - 5 2 ] .I ti s
possible that the reduction in FcgRIIb expression that we
observed on naïve B cells as a consequence of anti-TNF
therapy is accompanied by a decrease in the expression
of activating receptors on these cells, like TLR9 and
CD21, which would determine a restoration of the pro-
tective activator/inhibitor balance, but this issue needs to
be investigated. The effect of TNF blockage, however,
was not sufficient to prevent the downregulation of
FcgRIIb from naïve to memory B cells. These results are
in accordance with the fact that our group of patients did
not achieve a reduction in anti-MCV titers after 6
months of therapy. Others have reported that changes in
these antibodies become significant after 18 months of
anti-TNF therapy [53], so it is conceivable that a full nor-
malization of B-cell phenotype may become apparent
only over longer follow-up periods.
Conclusions
Our data demonstrate the existence of important altera-
tions in the phenotype of peripheral B cells from RA
patients, involving the expression of the co-stimulatory
molecule CD86 and the inhibitory receptor FcgRIIb, the
latter being associated with high titers of autoantibodies.
We consider that our study contributes relevant evi-
dence to a better comprehension of the molecular
mechanisms that are implied in the regulation of B cells
and the role that they play in the autoimmune response
elicited in RA.
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